« Previous
Next »
American Journal of Cardiology
Volume 104, Issue 12
, Pages 1647-1653
, 15 December 2009
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease and Chronic Kidney Disease
References
- . The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70:2021–2030
- . Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384
- . Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13–19
- . Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
- . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470
- . Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251
- . Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384
- NKF KDOQI Guidelines. www.kidney.org/professionals/kdoqi/guideline_diabetes/guide3.htmAccessed August 4, 2009
- 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with Chronic Stable angina. www.content.onlinejacc.org/cgi/reprint/j.jacc.2007.08.002v1.pdfAccessed August 4, 2009
- . Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary stenting and coronary artery bypass surgery and impact of diabetes. Circulation. 2002;106:2207–2211
- . Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92:509–514
- . Why is chronic kidney disease the spoiler for cardiovascular outcomes?. J Am Coll Cardiol. 2003;41:725–728
The trial was sponsored and oversight was provided by the Cooperative Studies Program of the US Department of Veterans Affairs Office of Research and Development. Additional funding was provided by the Canadian Institutes of Health Research. Supplemental corporate support consisted of unrestricted research grants payable to the Department of Veterans Affairs.
PII: S0002-9149(09)01474-X
doi: 10.1016/j.amjcard.2009.07.043
« Previous
Next »
American Journal of Cardiology
Volume 104, Issue 12
, Pages 1647-1653
, 15 December 2009
